Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Marksans Pharma Ltd

Pharmaceuticals & Biotechnology | Small Cap

Marksans Pharma Ltd Health Insights
Health Score : 7.24Health Score : 7.24

Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.

Latest Report

View All
Q2 FY26 Earnings Conference Call

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Marksans Pharma Ltd Health Insights
Health Score : 7.24Health Score : 7.24

Marksans Pharma Ltd demonstrates a mixed financial performance. The company shows strong liquidity and solvency, indicating a solid ability to meet its short-term and long-term obligations. Growth is robust, driven by strong revenue and profit increases. Profitability metrics are also excellent, reflecting efficient operations and healthy margins. However, efficiency ratios are weak, suggesting challenges in asset utilization. Financial ratios also need improvement, particularly in earnings per share, dividend, and capital expenditure management. Overall, while the company exhibits financial stability and growth potential, there are areas where operational efficiency and financial management could be enhanced. The company should focus on improving its asset turnover and managing capital expenditures more effectively to improve long-term financial health.

Latest Report

View All
Q2 FY26 Earnings Conference Call

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

39.11

Neutral

Industry Median

28.62

Neutral
Neutral

Small Cap Median

27.17

Neutral

P/E RATIO

28.16

P/B RATIO

3.89

Overvalued

Industry Median

3.17

Overvalued
Overvalued

Small Cap Median

2.62

Overvalued

P/S RATIO

3.99

Neutral

Industry Median

3.42

Neutral
Overvalued

Small Cap Median

2.55

Overvalued

Others

Neutral

PEG RATIO

0.00

Neutral
Overvalued

EV/EBITDA RATIO

16.23

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹259.67 as on Jun 20, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Concall Report14th Nov 25

Q2 FY26 Earnings Conference Call

BULLISH SENTIMENT

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

The company exhibits excellent growth, driven by strong revenue, operating profit, EPS, asset, and net income growth rates. This indicates the company is expanding its operations and profitability effectively. The company's prospects are very encouraging, reflecting its ability to capitalize on market opportunities and increase shareholder value. The company may be able to achieve higher growth rate in future.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate8.3624.2117.5520.4912.5
Operating Profit Growth Rate-23.8231.273515.2513.61
Earnings Per Share (EPS) Growth-21.730.3817.6921.399.76
Asset Growth Rate33.2233.8622.4220.8519.17
Net Income Growth Rate-21.7641.7118.8721.599.66
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 3.80

The company's financial ratios present a mixed picture. While adjusted and cash EPS are moderate, the book value per share is relatively low. Dividend per share and capital expenditures are also low, indicating potential areas for improvement in shareholder returns and investment strategies. The company may need to reassess its capital allocation decisions to enhance overall financial performance. Enhanced capital expenditure can improve efficiency and growth.

AverageAdjusted Earnings Per Share (Adjusted EPS)Average
WeakCash Earnings Per Share (Cash EPS)Weak
WeakBook Value Per ShareWeak
PoorDividend Per Share (DPS)Poor
PoorCapital Expenditures (CapEx)Poor
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)4.615.877.028.569.38
Cash Earnings Per Share (Cash EPS)5.667.048.6410.3611.53
Book Value Per Share29.3238.7845.8954.8267.18
Dividend Per Share (DPS)0.270.530.620.840
Capital Expenditures (CapEx)4654208172130
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 10.00

The company exhibits excellent profitability, driven by high gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This indicates efficient operations and effective cost management. The company's returns on capital and equity are robust, reflecting its ability to generate profits from its investments. The company is in very good state in terms of profitability.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
ExcellentReturn on Assets (ROA)Excellent
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin14.3515.5517.681717.01
Return on Capital Employed (ROCE)2322212019
Return on Equity (ROE)15.5615.1915.2515.5213.89
Return on Assets (ROA)15.8315.5317.1216.3315.57
Operating Margin17.3718.3621.0820.1720.37
Net Margin12.5414.3114.4714.614.23
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 3.00

The company's efficiency ratios are generally low, indicating potential issues with asset utilization. Low turnover ratios and high days sales in inventory and receivable days suggest the company is not effectively managing its assets to generate revenue. This could result in higher carrying costs and lower profitability. Improving asset management practices is essential to enhance overall financial performance. Efficient asset management can reduce cost and increase revenue.

PoorFixed Asset Turnover RatioPoor
WeakInventory Turnover RatioWeak
AverageReceivables Turnover RatioAverage
PoorDays Sales in Inventory RatioPoor
PoorReceivable DaysPoor
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio3.483.812.812.672.71
Inventory Turnover Ratio3.083.443.252.972.69
Receivables Turnover Ratio4.474.5655.284.98
Days Sales in Inventory Ratio118.51106.1112.31122.9135.69
Receivable Days81.6680.047369.1373.29
Capital Turnover Ratio1.171.010.950.950.88
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 10.00

The company's coverage ratios are excellent, demonstrating a strong ability to meet its interest and dividend obligations. The high interest coverage ratio indicates the company can easily cover its interest expenses. This provides financial flexibility and reduces the risk of default. The company is in very good state to pay off its debts.

ExcellentInterest Coverage RatioExcellent
ExcellentEquity Dividend Coverage RatioExcellent
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio3238.5639.554324.38
Equity Dividend Coverage Ratio16.6711.1111.1110
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company demonstrates excellent solvency, indicating a strong long-term financial stability. Low debt and high equity ratios suggest a conservative capital structure. The company relies more on equity than debt to finance its assets, reducing financial risk. This provides a solid foundation for future growth and stability. The company's ability to meet its long-term obligations is very secure, indicating financial resilience. The company's debt is very well managed and the company is growing well.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.050.040.090.110.09
Debt to Equity Ratio0.050.040.10.120.1
Equity Ratio0.950.960.910.890.91
Debt To Asset Ratio0.040.040.080.090.08
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 8.80

The company's liquidity position is generally strong, indicating a robust ability to meet its short-term obligations. High current, quick, and cash ratios reflect ample liquid assets. However, the operating cash flow ratio is relatively weak, suggesting a potential disconnect between earnings and operating cash flows. While the company can comfortably cover its immediate liabilities, generating more cash from operations could enhance its financial flexibility. The weighted average calculation gives more weight to recent performance, providing an accurate assessment of the current liquidity situation. The very high liquidity may also mean that the company is not efficiently using its assets to generate revenue.

ExcellentCurrent RatioExcellent
ExcellentQuick RatioExcellent
ExcellentCash RatioExcellent
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio3.314.654.664.75.26
Quick Ratio2.153.323.122.923.41
Cash Ratio0.961.961.681.491.89
Operating Cash Flow Ratio0.270.650.570.440.87
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 21 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Granules India Ltd7.7332.77Highly Overvalued1185.0016.17595.00
2FDC Ltd7.6422.52Neutral346.0017.56281.00
3Supriya Lifescience Ltd7.4635.88Highly Overvalued294.0025.98209.00
4Aarti Pharmalabs Ltd7.4635.90Neutral369.0019.44175.00
5Innova Captab Ltd7.3638.55Overvalued243.0014.63141.00
6Akums Drugs & Pharmaceuticals Ltd7.2837.30Overvalued522.007.09256.00
7Marksans Pharma Ltd7.2428.16Neutral601.006.64420.00
8Hikal Ltd7.13-51.71Neutral220.00-3.95-49.00
9RPG Life Sciences Ltd7.1232.70Neutral147.0069.64115.00
10Shilpa Medicare Ltd5.9444.32Highly Overvalued435.006.80243.00
11Strides Pharma Science Ltd5.5518.41Undervalued925.0019.92575.00
12Jeena Sikho Lifecare Ltd5.5231.22Neutral349.0017.87222.00
13Gufic BioSciences Ltd5.4955.51Neutral151.006.3064.00
14Dishman Carbogen Amcis Ltd5.3827.45Neutral566.00-2.4597.00
15Aarti Drugs Ltd5.0717.34Undervalued309.0018.54195.00
16Orchid Pharma Ltd4.85241.74Neutral41.008.9121.00
17Sequent Scientific Ltd4.61293.05Overvalued162.000.6332.00
18Sun Pharma Advanced Research Company Ltd4.354.97Neutral1599.0047.831553.00
19Zota Health Care Ltd3.97-61.25Neutral19.008.06-74.00
20Procter & Gamble Health Ltd3.4531.71Neutral457.00196.94327.00
21Sanofi India Ltd3.4518.59Neutral491.00134.52413.00
Management Assessment Summary
OrangeBalanced Management

Marksans Pharma's management demonstrates mixed effectiveness. Strong sales and profit growth indicate capable leadership, while increasing institutional interest reflects confidence in the company's prospects. However, rising debt levels and a lengthening cash conversion cycle present challenges. Although strategic investments are evident, inefficiencies in working capital management raise concerns. Overall, management effectiveness is rated as Orange due to these counterbalancing factors.

Category Metric Value Assessment
PROS Compounded Sales Growth (TTM) 20% Demonstrates strong revenue expansion
FII Holding (Mar 2025) 22.19% Indicates growing institutional confidence
CONS Cash Conversion Cycle (Mar 2025) 247 days Suggests inefficient working capital management
Borrowings (Mar 2025) ₹ 322 Cr Indicates increasing financial leverage
ExcellentFinancial Performance & GrowthExcellent
GoodCapital Efficiency & ReturnsGood
AverageFinancial Health & PrudenceAverage
AverageStrategic & Operational IndicatorsAverage
GoodShareholding & Ownership StructureGood
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Strategic & Operational Indicators

05.

Shareholding & Ownership Structure

Risk Assessment Summary
OrangeBalanced Risk

Marksans Pharma faces moderate risks. Increasing debt levels and a lengthening cash conversion cycle present financial and operational challenges. Consistent sales and profit growth, along with rising institutional interest, provide some mitigation. The risk assessment is rated as Orange, indicating the need for monitoring.

AverageOff-balance sheet exposure quantificationAverage
AverageContingent liability evaluationAverage
01.

Off-balance sheet exposure quantification

02.

Contingent liability evaluation

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10260.45Bearish
  3. SMA 20257.87Bullish
  4. SMA 50253.39Bullish
  5. EMA 10259.76Bearish
  6. EMA 20257.98Bullish
  7. EMA 50253.71Bullish
  8. DEMA 10260.98Bearish
  9. DEMA 20261.38Bearish
  10. DEMA 50259.74Bearish
  11. TEMA 10260.05Bearish
  12. TEMA 20261.96Bearish
  13. TEMA 50260.18Bearish
  14. MACD2.48Bearish
  15. ADX43.71Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI57.43Neutral
  3. CCI25.07Neutral
  4. ROC 9-0.58Bearish
  5. ROC 141.57Bullish
  6. ROC 254.57Bullish
  7. Stoch K49.72Neutral
  8. Stoch D59.75Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper267.39Neutral
  3. BB Middle257.87Neutral
  4. BB Lower248.35Neutral
  5. ATR3.06Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI71.62Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10259.48Bearish
  3. SMA 20254.29Bullish
  4. SMA 50248.54Bullish
  5. EMA 10258.46Bullish
  6. EMA 20255.69Bullish
  7. EMA 50249.14Bullish
  8. DEMA 10261.28Bearish
  9. DEMA 20260.27Bearish
  10. DEMA 50260.02Bearish
  11. TEMA 10261.37Bearish
  12. TEMA 20261.22Bearish
  13. TEMA 50259.15Bearish
  14. MACD3.52Bullish
  15. ADX43.97Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI61.51Neutral
  3. CCI65.79Neutral
  4. ROC 91.69Bullish
  5. ROC 144.80Bullish
  6. ROC 253.72Bullish
  7. Stoch K68.88Neutral
  8. Stoch D70.79Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper265.58Neutral
  3. BB Middle254.29Neutral
  4. BB Lower243.01Neutral
  5. ATR4.26Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI64.79Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 10254.06Bullish
  3. SMA 20251.16Bullish
  4. SMA 50238.50Bullish
  5. EMA 10255.60Bullish
  6. EMA 20251.21Bullish
  7. EMA 50237.68Bullish
  8. DEMA 10260.03Bearish
  9. DEMA 20259.34Bearish
  10. DEMA 50260.01Bearish
  11. TEMA 10260.96Bearish
  12. TEMA 20258.96Bullish
  13. TEMA 50N/AN/A
  14. MACD6.07Bullish
  15. ADX63.13Strong Trend
Momentum Indicators (7)
  1. IndicatorValueSignal
  2. RSI65.00Neutral
  3. CCI123.59Overbought
  4. ROC 93.44Bullish
  5. ROC 144.44Bullish
  6. ROC 256.20Bullish
  7. Stoch K74.99Neutral
  8. Stoch D76.64Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper263.92Neutral
  3. BB Middle251.16Neutral
  4. BB Lower238.40Neutral
  5. ATR7.04Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI86.60Overbought

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (22)
  1. IndicatorValueSignal
  2. SMA 10251.07Bullish
  3. SMA 20244.38Bullish
  4. SMA 50212.97Bullish
  5. SMA 100192.37Bullish
  6. SMA 200186.12Bullish
  7. EMA 10251.38Bullish
  8. EMA 20242.30Bullish
  9. EMA 50220.48Bullish
  10. EMA 100204.76Bullish
  11. EMA 200199.88Bullish
  12. DEMA 10259.28Bullish
  13. DEMA 20259.65Bullish
  14. DEMA 50246.25Bullish
  15. DEMA 100221.11Bullish
  16. DEMA 200198.54Bullish
  17. TEMA 10259.07Bullish
  18. TEMA 20260.65Bearish
  19. TEMA 50260.36Bearish
  20. TEMA 100241.41Bullish
  21. TEMA 200205.01Bullish
  22. MACD12.64Bearish
  23. ADX38.02Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI67.44Neutral
  3. CCI121.93Overbought
  4. ROC 148.79Bullish
  5. ROC 2528.60Bullish
  6. Stoch K83.25Overbought
  7. Stoch D74.60Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper268.39Neutral
  3. BB Middle244.38Neutral
  4. BB Lower220.37Neutral
  5. ATR11.61Low Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI63.01Neutral

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bearish

Trend Indicators (10)
  1. IndicatorValueSignal
  2. SMA 20190.01Bullish
  3. SMA 50190.40Bullish
  4. EMA 20200.73Bullish
  5. EMA 50197.42Bullish
  6. DEMA 20215.02Bullish
  7. DEMA 50193.14Bullish
  8. TEMA 20232.19Bullish
  9. TEMA 50190.41Bullish
  10. MACD13.15Bullish
  11. ADX27.59Strong Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI65.36Neutral
  3. CCI182.11Overbought
  4. ROC 1447.54Bullish
  5. ROC 2538.04Bullish
  6. Stoch K81.28Overbought
  7. Stoch D81.45Overbought
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper242.21Overbought
  3. BB Middle190.01Neutral
  4. BB Lower137.81Neutral
  5. ATR19.60High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI85.58Overbought

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Market Sentiment

Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe

Trend Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Strong Bullish

Momentum Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bullish

Volatility Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Bearish

Volume Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Trend Indicators (14)
  1. IndicatorValueSignal
  2. SMA 6184.30Bullish
  3. SMA 12191.53Bullish
  4. SMA 24220.16Bullish
  5. EMA 6196.73Bullish
  6. EMA 12196.47Bullish
  7. EMA 24193.36Bullish
  8. DEMA 6204.95Bullish
  9. DEMA 12192.11Bullish
  10. DEMA 24212.63Bullish
  11. TEMA 6219.84Bullish
  12. TEMA 12188.38Bullish
  13. TEMA 24195.56Bullish
  14. MACD31.80Bearish
  15. ADX24.01Weak Trend
Momentum Indicators (6)
  1. IndicatorValueSignal
  2. RSI58.56Neutral
  3. CCI81.55Neutral
  4. ROC 2548.49Bullish
  5. ROC 50441.08Bullish
  6. Stoch K29.79Neutral
  7. Stoch D53.25Neutral
Volatility Indicators (4)
  1. IndicatorValueSignal
  2. BB Upper319.67Neutral
  3. BB Middle218.83Neutral
  4. BB Lower117.98Neutral
  5. ATR41.49High Volatility
Volume Indicators (1)
  1. IndicatorValueSignal
  2. MFI61.78Neutral